JUBILANT PHARMOVA
|
JUBILANT PHARMOVA Last 5 Year Financial Ratios History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 53.13 | 4.88 | -3.84 | 26.01 | 52.51 |
| CEPS(Rs) | 76.26 | 28.77 | 30.76 | 49.93 | 57.98 |
| DPS(Rs) | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 |
| Book NAV/Share(Rs) | 394.94 | 343.00 | 339.19 | 333.91 | 297.84 |
| Tax Rate(%) | 14.72 | 57.36 | 333.45 | 34.49 | 34.12 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 16.22 | 13.44 | 12.36 | 18.86 | 22.90 |
| EBIT Margin(%) | 16.88 | 6.61 | 3.44 | 12.66 | 17.30 |
| Pre Tax Margin(%) | 13.55 | 2.54 | 0.44 | 10.28 | 14.28 |
| PAT Margin (%) | 11.56 | 1.08 | -1.03 | 6.74 | 9.41 |
| Cash Profit Margin (%) | 16.65 | 6.78 | 7.79 | 12.96 | 15.13 |
| Performance Ratios | |||||
| ROA(%) | 7.02 | 0.65 | -0.63 | 4.44 | 5.45 |
| ROE(%) | 14.35 | 1.34 | -1.21 | 8.21 | 11.09 |
| ROCE(%) | 13.92 | 5.02 | 2.53 | 9.97 | 12.02 |
| Asset Turnover(x) | 0.61 | 0.60 | 0.61 | 0.66 | 0.58 |
| Sales/Fixed Asset(x) | 0.92 | 0.88 | 0.89 | 0.95 | 0.86 |
| Working Capital/Sales(x) | 5.38 | 3.85 | 3.16 | 3.20 | 3.20 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 1.08 | 1.14 | 1.12 | 1.05 | 1.16 |
| Receivable days | 45.59 | 51.11 | 54.89 | 52.04 | 63.24 |
| Inventory Days | 61.02 | 72.70 | 76.56 | 70.98 | 89.02 |
| Payable days | 146.59 | 143.02 | 134.99 | 133.47 | 191.38 |
| Valuation Parameters | |||||
| PER(x) | 16.80 | 116.50 | - | 14.91 | 12.96 |
| PCE(x) | 11.71 | 19.76 | 9.07 | 7.77 | 11.74 |
| Price/Book(x) | 2.26 | 1.66 | 0.82 | 1.16 | 2.28 |
| Yield(%) | 0.56 | 0.88 | 1.79 | 1.29 | 0.73 |
| EV/Net Sales(x) | 2.14 | 1.71 | 1.09 | 1.32 | 2.09 |
| EV/Core EBITDA(x) | 12.56 | 11.80 | 8.39 | 6.95 | 9.01 |
| EV/EBIT(x) | 12.66 | 25.83 | 31.63 | 10.46 | 12.08 |
| EV/CE(x) | 1.78 | 1.29 | 0.78 | 0.83 | 1.45 |
| M Cap / Sales | 1.95 | 1.34 | 0.71 | 1.01 | 1.78 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 7.93 | 6.71 | 2.47 | 0.52 | 2.05 |
| Core EBITDA Growth(%) | 26.92 | 19.03 | -30.24 | -17.43 | -10.80 |
| EBIT Growth(%) | 175.72 | 105.00 | -72.16 | -26.46 | -12.98 |
| PAT Growth(%) | 1,050.34 | 212.02 | -115.71 | -28.03 | -15.33 |
| EPS Growth(%) | 988.73 | 227.19 | -114.75 | -50.48 | -6.88 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.39 | 0.63 | 0.63 | 0.55 | 0.55 |
| Current Ratio(x) | 1.62 | 1.92 | 2.12 | 2.20 | 2.82 |
| Quick Ratio(x) | 1.10 | 1.24 | 1.34 | 1.42 | 1.74 |
| Interest Cover(x) | 5.08 | 1.63 | 1.15 | 5.33 | 5.73 |
| Total Debt/Mcap(x) | 0.17 | 0.38 | 0.77 | 0.47 | 0.24 |
Compare Financial Ratios of peers of JUBILANT PHARMOVA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| JUBILANT PHARMOVA | ₹17,553.3 Cr | -4% | -5.9% | 30.9% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹380,702.0 Cr | -3.3% | -4.6% | -7.9% | Stock Analytics | |
| DIVIS LABORATORIES | ₹156,908.0 Cr | -9% | -13.6% | 24% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹120,896.0 Cr | -1.1% | 7% | 8.2% | Stock Analytics | |
| CIPLA | ₹119,988.0 Cr | -2% | 0.6% | -4% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹101,122.0 Cr | -1.1% | -3.8% | -13.3% | Stock Analytics | |
JUBILANT PHARMOVA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| JUBILANT PHARMOVA | -4% |
-5.9% |
30.9% |
| SENSEX | -0.9% |
-4.4% |
1.6% |
You may also like the below Video Courses
